Identification of stem cells from oncogenic mouse lungs by epithelial growth factor receptor gene mutation

• Project/Area Number: 24659404
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Okayama University
• Principal Investigator: SATO AKIKO 岡山大学, 医歯薬学総合研究科, 助教 (30623532)
• Co-Investigator(Kenkyū-buntansha): 木浦 勝行 岡山大学, 大学病院, 教授 (10243502) ; 伊藤 隆明 熊本大学, 大学院生命科学研究部(医), 教授 (70168392)
• Project Period (FY): 2012-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000); Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: BASCs / EGFR遺伝子変異改変マウス / 器官培養 / EGFR遺伝子改変マウス / マウスEGFR遺伝子改変マウス / EGFR遺伝子変異 / EGFRチロシンリン酸化酵素阻害剤 / マウスEgfr遺伝子改変マウス / EGFRチロシンリン酸化酵素阻害薬 / 胎仔の器官培養 / 肺がん幹細胞

Outline of Final Research Achievements

We used fetuses born by genetically modified mouse (♂) and wild type C57BL / 6 mouse (♀) which introduced EGFR gene mutation (mouse EGFRExon 19 delE 748 - A 752 and human EGFRExon 21 L 858 R) respectively established in the applicant 's laboratory, Researcher Fetal lung was excised and organ culture was carried out under the guidance of Professor Takaaki Ito of Kumamoto University. Carcinogenesis in the process of lung development was confirmed directly. In the future, we plan to add EGFR-TKI to a culture using a part of the lung cancer tissue of fetal lung and investigate changes in EGFR-TKI susceptibility using MTT assay, Western blotting method, immunostaining etc.

Research Products

• [Journal Article] Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung Cancer. (2015)
  • Author(s): Minami D, Takigawa N, Morichika D, Kubo T, Ohashi K, Sato A, Hotta K, Tabata M, Tanimoto M, Kiura K.
  • Journal Title: Respir Investig. Volume: 53 Issue: 3 Pages: 93-97
  • DOI: 10.1016/j.resinv.2014.10.003
  • Peer Reviewed / Open Access
• [Journal Article] Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. (2014)
  • Author(s): Kato Y, Hotta K, Takigawa N, Nogami N, Kozuki T, Sato A, Ichihara E, Kudo K, Oze I, Tabata M, Shinkai T, Tanimoto M, Kiura K.
  • Journal Title: Cancer Chemother Pharmacol. Volume: 73 Issue: 5 Pages: 943-950
  • DOI: 10.1007/s00280-014-2425-9
  • Peer Reviewed / Open Access
• [Presentation] Acquired Resistance to a New ALK Inhibitor, Alectinib in Lung Cancer (2014)
  • Author(s): Hideko Isozaki, Eiki Ichihara, Kadoaki Ohashi, Ochi Nobuaki, Toshio Kubo, Daisuke Minami, Hiromichi Yamane, Akiko-Hisamoto Sato, Kenichiro Kudo, Yuka Kato, Masayuki Yasugi, Katsuyuki Hotta, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, and Katsuyuki Kiura
  • Organizer: European Society for Medical Oncology
  • Place of Presentation: Madrid, Spain
  • Year and Date: 2014-09-26 – 2014-09-30